CRESCENT BIOPHARMA, INC. Revenues
CRESCENT BIOPHARMA, INC. (CBIO) reported Revenues of $18.50 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-06.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2018-11-02
- CRESCENT BIOPHARMA, INC. revenues for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- CRESCENT BIOPHARMA, INC. revenues for the quarter ending 2016-09-30 was $18.50K.
- CRESCENT BIOPHARMA, INC. revenues for the quarter ending 2015-12-31 was $35.38K.
- CRESCENT BIOPHARMA, INC. revenues for the quarter ending 2015-09-30 was $0.00.
- CRESCENT BIOPHARMA, INC. revenues for fiscal 2016 was $18.50K, a 99.91% decline from fiscal 2015.
- CRESCENT BIOPHARMA, INC. revenues for fiscal 2015 was $20.07M, a 33.56% increase from fiscal 2014.
- CRESCENT BIOPHARMA, INC. revenues for fiscal 2014 was $15.03M, a 276.37% increase from fiscal 2013.
- CRESCENT BIOPHARMA, INC. revenues for fiscal 2013 was $3.99M, a 73.83% decline from fiscal 2012.
| Period end | Revenues 1 month | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 9 month | Revenues 12 month | Revenues 130 month |
|---|---|---|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $18.50K derived: sum of 2 quarters · filed 2018-03-06 | $18.50K 10-K · filed 2018-03-06 | ||||
| 2016-09-30 | $18.50K 10-K · filed 2018-03-06 | $18.50K 10-Q · filed 2017-11-08 | |||||
| 2015-12-31 | $35.38K 10-K · filed 2017-03-01 | $35.38K derived: sum of 2 quarters · filed 2017-03-01 | $20.07M derived: sum of 3 quarters · filed 2017-03-01 | $20.07M 10-K · filed 2018-03-06 | |||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $20.04M derived: sum of 2 quarters · filed 2017-03-01 | $20.04M 10-Q · filed 2016-11-04 | $20.04M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2015-06-30 | $20.00M 10-Q · filed 2018-11-02 | $20.04M 10-K · filed 2017-03-01 | $20.04M 10-Q · filed 2016-08-04 | $20.04M derived: sum of 3 quarters · filed 2017-03-01 | $20.04M derived: sum of 4 quarters · filed 2017-03-01 | ||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-05 | $0.00 derived: sum of 2 quarters · filed 2017-03-01 | $0.00 derived: sum of 3 quarters · filed 2017-03-01 | $15.03M derived: sum of 4 quarters · filed 2017-03-01 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $0.00 derived: sum of 2 quarters · filed 2017-03-01 | $15.03M derived: sum of 3 quarters · filed 2017-03-01 | $15.03M 10-K · filed 2017-03-01 | |||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $15.03M derived: sum of 2 quarters · filed 2016-02-29 | $15.03M 10-Q · filed 2015-11-12 | $15.10M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $15.03M 10-K · filed 2016-02-29 | $15.03M 10-Q · filed 2015-08-06 | $15.10M derived: sum of 3 quarters · filed 2016-02-29 | $15.16M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-05-31 | $15.00M 10-Q · filed 2018-11-02 | ||||||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-05 | $77.41K derived: sum of 2 quarters · filed 2015-05-05 | $129.98K derived: sum of 3 quarters · filed 2015-05-05 | $185.06K derived: sum of 4 quarters · filed 2015-05-05 | $23.59M 10-Q · filed 2014-05-09 | ||
| 2013-12-31 | $77.41K 10-K · filed 2015-03-16 | $129.98K derived: sum of 2 quarters · filed 2015-03-16 | $185.06K derived: sum of 3 quarters · filed 2015-03-16 | $3.99M 10-K · filed 2016-02-29 | |||
| 2013-09-30 | $52.57K 10-K · filed 2015-03-16 | $107.64K derived: sum of 2 quarters · filed 2015-03-16 | $3.92M 10-Q · filed 2014-10-31 | ||||
| 2013-06-30 | $55.07K 10-K · filed 2015-03-16 | $3.86M 10-Q · filed 2014-07-31 | |||||
| 2013-03-31 | $3.81M 10-K · filed 2015-03-16 | $3.81M 10-Q · filed 2014-05-09 | |||||
| 2012-12-31 | $15.26M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |